Angle plc (AGL) Ordinary 10p
![](https://online.hl.co.uk/img/hl/layout/security-down-arrow.gif)
- Add to watchlist
- Create an alert
- This stock can be held in a
![](https://online.hl.co.uk/img/hl/layout/security-down-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
![](https://online.hl.co.uk/img/hl/layout/security-down-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
Share news, reports & tips
-
Angle unveils plans to raise more than £10m
5 June 2024 10:08
(Sharecast News) - Liquid biopsy specialist Angle is to raise more than £10m to support future growth, the UK company announced on Wednesday.
-
Angle reports promising results from Parsortix study
16 May 2024 11:46
(Sharecast News) - Angle, the AIM-listed liquid biopsy company which specialises in circulating tumour cell (CTC) solutions, has announced the results of a clinical study which show that its Parsortix system...
-
Angle strikes supplier deal with AstraZeneca
3 May 2024 07:58
(Sharecast News) - Liquid biopsy technology firm Angle has struck a supplier deal with pharmaceutical giant AstraZeneca to develop an androgen receptor detection assay to enhance prostate cancer studies.
-
Angle granted European patent for CellKeep, US patent imminent
22 April 2024 06:59
(Sharecast News) - Liquid biopsy specialist Angle announced on Monday that it has received a European patent for its 'CellKeep' slide, as it anticipated the imminent grant of an equivalent US...
-
Angle receives 'breakthrough results' from DNA molecular analysis
4 January 2024 07:58
(Sharecast News) - Liquid biopsy company Angle received "breakthrough results" from DNA molecular analysis of cancer patient blood samples on Thursday, sending its shares skywards as a result.
-
Angle locks in $250,000 contract with Eisai
2 January 2024 09:04
(Sharecast News) - Liquid biopsy company Angle has locked in a $250,000 contract with global pharmaceutical company Eisai to deliver circulating tumour cell analysis in a pilot study.
-
Angle losses widen in 'breakthrough year'
21 April 2023 11:06
(Sharecast News) - Liquid biopsy specialist Angle described a "breakthrough year" in its 2022 results on Friday, with both FDA clearance and positive results from the ovarian cancer study being...
-
Tougher market conditions impacting Angle clients
5 January 2023 16:09
(Sharecast News) - Liquid biopsy specialist Angle said in an update on Thursday that actions taken to control its cost base, and the closure of its Canadian operations, left it on track to deliver expected...
-
Director dealings: Angle CEO, finance chief join capital raise
19 July 2022 16:35
(Sharecast News) - Liquid biopsy specialist Angle had two entries on the list of director buys on Tuesday, after its chief executive and chief financial officers invested in shares.
-
Angle wins additional contract with large-scale pharma company
22 June 2022 10:27
(Sharecast News) - Liquid biopsy company Angle has secured an additional contract with its first large-scale pharmaceutical services customer.
-
Angle's Parsortix to be used in 'significant' prostate cancer study
20 May 2022 13:07
(Sharecast News) - Liquid biopsy company Angle announced on Friday that Prostate Cancer UK has approved funding for a "significant" clinical study at the Barts Cancer Institute of the Queen Mary...
Company announcements Announcements
-
Standard form for notification of major holdings
18 July 2024 10:08
Angle
-
Standard form for notification of major holdings
12 July 2024 15:38
Angle
-
Result of 2024 Annual General Meeting
11 July 2024 15:07
Angle
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.